Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EPS (Weighted Average and Diluted) (2019 - 2025)

Editas Medicine (EDIT) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.25 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 66.67% to -$0.25 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.35, a 7.48% increase, with the full-year FY2024 number at -$2.88, down 42.57% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.25 for Q3 2025 at Editas Medicine, up from -$0.63 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.21 in Q4 2023 to a low of -$0.92 in Q1 2025.
  • A 5-year average of -$0.67 and a median of -$0.74 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 575.0% in 2021, then soared 76.14% in 2023.
  • Editas Medicine's EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then plummeted by 44.26% to -$0.88 in 2022, then skyrocketed by 76.14% to -$0.21 in 2023, then plummeted by 161.9% to -$0.55 in 2024, then skyrocketed by 54.55% to -$0.25 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's EPS (Weighted Average and Diluted) are -$0.25 (Q3 2025), -$0.63 (Q2 2025), and -$0.92 (Q1 2025).